<SUBMISSION>
<ACCESSION-NUMBER>0001023024-05-000010
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050516
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20050516
<DATE-OF-FILING-DATE-CHANGE>20050516
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>05832304
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>biosanteq1.htm
<DESCRIPTION>BIOSANTE !ST QUARTER 2005 EARNINGS RELEASE
<TEXT>
<HTML><HEAD><TITLE>BioSante !st Quarter 2005 Earnings release</TITLE><!-- Licensed to: BioSante Pharmaceuticals--><!-- Document Created using EDGARIZER HTML --><!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.--><!-- All rights reserved EDGARfilings.com --></HEAD>
<BODY id=38>
<DIV><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>
<DIV>
<DIV>
<HR align=left width="100%" color=#000000 noShade SIZE=5>
</DIV></DIV></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><STRONG>UNITED STATES</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SECURITIES AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Washington, D.C. 20549</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">__________________</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif"><STRONG>FORM 8-K</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Current Report</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">__________________</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Date of Report (Date of earliest event reported): </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>May&nbsp;16, 2005</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman, serif"><STRONG>BIOSANTE PHARMACEUTICALS, INC.</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Exact name of registrant as specified in its charter)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Delaware</STRONG></FONT></DIV></TD>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>1-31812</STRONG></FONT></DIV></TD>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>58-2301143</STRONG></FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(State or other jurisdiction of incorporation)</FONT></DIV></TD>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Commission File Number)</FONT></DIV></TD>
<TD vAlign=top align=middle width="27%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(I.R.S. Employer Identification Number)</FONT></DIV></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR>
<TD vAlign=top align=middle width="40%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>111 Barclay Boulevard</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Lincolnshire, Illinois</STRONG></FONT></DIV></TD>
<TD vAlign=top align=middle width="40%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>60069</STRONG></FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=middle width="40%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Address of principal executive offices)</FONT></DIV></TD>
<TD vAlign=top align=middle width="40%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Zip Code)</FONT></DIV></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>(847) 478-0500</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Registrant&#146;s telephone number, including area code)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>N/A</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Former name or former address, if changed since last report)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><U></U></FONT>&nbsp;</DIV>
<DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=#000000 noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Section&nbsp;2 &#151; Financial Information</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Item 2.02</STRONG></FONT><FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 36pt">&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 4.5pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Results of Operations and Financial Condition</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;On May 16, 2005, BioSante Pharmaceuticals, Inc. publicly announced its financial results for the first quarter ended March 31, 2005.&nbsp; For further information, please refer to the press release attached hereto as Exhibit 99.1, which is incorporated by reference herein.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>
<DIV align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;The information contained in this report and the exhibit hereto shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filings made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. </FONT></FONT><BR></DIV></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG></STRONG></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Section 9 &#151; Financial Statements and Exhibits</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Item 9.01</STRONG></FONT><FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 36pt">&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Financial Statements and Exhibits</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%" border=0>
<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 72pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(c)&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Exhibits.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 4.3pt" align=justify><BR></DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=1>
<TR>
<TD style="BORDER-BOTTOM: black thin solid" vAlign=top width="11%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>Exhibit No.</STRONG></FONT></DIV></TD>
<TD style="BORDER-BOTTOM: black thin solid" vAlign=top width="60%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Description</STRONG></FONT></DIV></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: black thin solid" vAlign=top width="11%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">99.1</FONT></DIV></TD>
<TD style="BORDER-BOTTOM: black thin solid" vAlign=top width="60%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Press release issued May 16, 2005.</FONT></DIV></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=#000000 noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SIGNATURE</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>BIOSANTE PHARMACEUTICALS, INC.</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff border=0>
<TR vAlign=top bgColor=#ffffff>
<TD width="50%"><FONT size=2>&nbsp;</FONT></TD>
<TD width="1%"><FONT size=2>&nbsp;</FONT></TD>
<TD width="49%"><FONT size=2>&nbsp;</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT size=2>&nbsp;</FONT></TD>
<TD colSpan=2><FONT size=2><STRONG></STRONG></FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT size=2>&nbsp;<BR>&nbsp;</FONT></TD>
<TD><FONT size=2>&nbsp;<BR>&nbsp;</FONT></TD>
<TD><FONT size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD><FONT size=2>Date:&nbsp;May 16, 2005</FONT></TD>
<TD><FONT size=2>By:&nbsp;&nbsp;</FONT></TD>
<TD><FONT size=2>/s/ Phillip B. Donenberg</FONT></TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD colSpan=2><FONT size=1>&nbsp;</FONT></TD>
<TD align=left>
<HR align=left width="80%" color=#000000 noShade SIZE=2>
</TD></TR>
<TR vAlign=top bgColor=#ffffff>
<TD colSpan=2><FONT size=2>&nbsp;</FONT></TD>
<TD><FONT size=2>Chief Financial Officer, Treasurer, and Secretary</FONT></TD></TR></TABLE></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=#000000 noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>
<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>BIOSANTE PHARMACEUTICALS, INC.</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>FORM 8-K</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>EXHIBIT INDEX</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><U>Exhibit No.</U></STRONG>&nbsp;&nbsp;&nbsp;&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;<U>&nbsp;&nbsp;&nbsp;</U></FONT><STRONG><U>Description&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;<U>&nbsp;&nbsp; Method of Filing<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</U><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>99.1&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;Press Release issued&nbsp;May 16, 2005&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;Filed herewith</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align=justify>&nbsp;</DIV></DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease5-16.htm
<DESCRIPTION>BIOSANTE PHARMA EARNINGS PRESS RELEASE 5/16/05
<TEXT>
<HTML><HEAD><TITLE>BioSante Pharma Earnings press release 5/16/05</TITLE><!-- Licensed to: BioSante Pharmaceuticals--><!-- Document Created using EDGARIZER HTML --><!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.--><!-- All rights reserved EDGARfilings.com --></HEAD>
<BODY id=38><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>BioSante Pharmaceuticals, Inc.&nbsp;</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">&nbsp;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>FOR IMMEDIATE RELEASE&nbsp;</STRONG></FONT>&nbsp;<FONT style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG> Amex: BPA</STRONG></FONT><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG><IMG src="biosantelogo6.jpg"><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;<FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</STRONG></FONT><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG></STRONG></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>BioSante Pharmaceuticals Reports Product Development Highlights</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>and First Quarter 2005 Financial Results</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>LINCOLNSHIRE, Illinois (May 16, 2005) -</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"> BioSante Pharmaceuticals</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> (AMEX: BPA) today reported on certain product development highlights and announced </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">financial results for the first quarter ended March 31, 2005. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#147;The completion of our pivotal Phase III clinical trial of Bio-E-Gel</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman, serif"><SUP>&#153;</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante,&#148; said Stephen M. Simes, BioSante&#146;s president and chief executive officer. &#147;We look forward to reporting the results of the Bio-E-Gel trial and continuing the development of our innovative CaP program. We also are working actively on our LibiGel</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman, serif"><SUP>&#153;</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> Phase III development plan in order to initiate Phase III clinical trials by year-end 2005.&#148;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>Product Development Highlights</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">-- BioSante announced the completion of its 12-week, 483-patient pivotal Phase III clinical trial to evaluate the safety and efficacy of Bio-E-Gel (bioidentical estradiol transdermal gel) for the treatment of moderate-to-severe hot flashes in menopausal women. &nbsp; BioSante&#146;s multicenter, randomized, double-blind, placebo-controlled trial of Bio-E-Gel was conducted in the United States and Canada.&nbsp; The study included three doses of Bio-E-Gel to maximize the safety profile by identifying the lowest effective dose. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">-- BioSante announced a new manufacturing agreement with a U.S.-based current good manufacturing practices (cGMP) manufacturer for large-scale quantities of its calcium phosphate-based nanotechnology (CaP). The CaP technology will be used to expand testing by a global pharmaceutical company in the development of an oral formulation of a currently marketed injectable protein product. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">-- The Company</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> presented new data from a study of BioVant&#153;, the company&#146;s patented calcium phosphate (CaP) nanoparticle technology at the annual World Vaccine Congress in Montreal. The main focus of the presentation was the intranasal mucosal surface delivery of an anthrax vaccine, and highlighted the simultaneous immune enhancement (i.e. immune adjuvant) effects and non-injected vaccine delivery potential of CaP. The anthrax vaccine is being developed under a subcontract with DynPort Vaccine Company for the U.S. Department of Defense.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>First Quarter 2005 Financial Overview</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">BioSante incurred a net loss of approximately $2.8 million or ($0.14) per share for the quarter ended March 31, 2005, compared to a net loss of $2.4 million or ($0.17) per share for the same period in 2004. The increase in the net loss is largely the result of increased research and development expenses incurred primarily as a result of completing the Phase III Bio-E-Gel trial. The Company&#146;s cash, cash equivalents and short-term investments as of March 31, 2005 were approximately $15 million, compared to $8.3 million at March 31, 2004. The Company&#146;s current average cash burn rate of $800,000 per month is expected to remain consistent through 2005.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -4.5pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>About BioSante Pharmaceuticals, Inc. </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante&#146;s lead products include Bio-E-Gel</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman, serif"><SUP>&#153;</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman, serif"><SUP>&#153;</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"> (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman, serif"><U>www.biosantepharma.com</U></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><EM>This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 19 to 31 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference. </EM></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><EM>All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</EM></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><STRONG>For more information, please contact: </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">Phillip Donenberg, BioSante Pharmaceuticals, Inc.; (847) 478-0500; donenber@biosantepharma.com</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -18pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">Ritu S. Baral, The Trout Group LLC; (212) 477-9007 ext 25; rbaral@troutgroup.com</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">Daniel Budwick, BMC Communications; (212) 477-9007 ext 14; </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; COLOR: #0000ff; FONT-FAMILY: Times New Roman, serif"><U>dbudwick@bmccommunications.com</U></FONT></DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>BIOSANTE LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"/`5(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#S?_A-/%?_
M`$,VL_\`@?+_`/%4'QKXK'_,S:U_X'R__%5A4'I7UWLX=D(]4T_PU\6=4TZU
MO[76]1:WN(EFC<ZP>C?,,C?Z5/\`\(7\8O\`H+ZA_P"#IO\`XNO9O`9SX!\/
M$\G^S;?G_@`J]J'B'1](=4U/5K&R=QN5;FY2,M],FO`EC:BFXJ*T\AGA?_"%
M_&+_`*"^H?\`@[;_`.+I&\&_&5!QJ6J2?36L?^SU[5_PF_A7_H9M&_\``^/_
M`!J>R\3:#J<HAL-;TRYD)QM@NXW;\@33>-K+>*_\!)LCYNUG_A9_AV)I-6OO
M$EO&HYF^W2/&OU=6V_\`CU87_":^*_\`H9M9_P#`^7_XJOL-X8I$9'C5D;[R
MLN0?J*^7/BMX.@\(^*`;)%CL+Y3-#$3PA'WU'H.5Q_O>U=>$QD:SY)Q28[%W
M0M(^*7B72H]2TS7-2FM9&*ASJ[*?E]O,JMXEC^(WA*&";6->U6);ABD6W5'?
MISV<=J]-^$>NZ19?#VU@O-5L;>59I,I+<(C8)X^\U<]\==7TS5--T9+'4;2[
MV3NS"WF63:-O7AJBG7J2Q'LW%6]`L>7_`/":^*_^AFUG_P`#Y?\`XJC_`(33
MQ7_T,VL_^!\O_P`56%17K>SAV0&[_P`)IXK_`.AFUG_P/E_^*H_X33Q7_P!#
M-K/_`('R_P#Q585%'LX=D!N_\)KXK_Z&;6?_``/E_P#BJ/\`A-?%7_0SZS_X
M'R__`!587UK;\'^'I/%7BFPT@$A)7S*0,8C'+?CBE-4X1<FEH!IZ3JOQ"U^;
MRM)U;Q%>/GDPW<K*OU;<%%=7%X/^,;KN;4=5CS_#)K?/Z/7O>EZ39Z+IT6GV
M%O'!;QKM"#O[D]S]:9J.M:9I$8;4-3L[0'^*YG6//YUX<\?)R_=P5O0+'A/_
M``A?QB_Z"^H?^#MO_BZ/^$+^,7_07U#_`,';?_%U[3_PF_A7_H9M&_\``^/_
M`!H_X3;PK_T,VC?^!\7^-+ZY6_D7W"LCQ8>"_C$2!_:^H<_]1MO_`(NN)U#Q
M/XRTW4)[&Z\1:PDT#F.1!J,IY'H=U?3X\;>%,_\`(S:-_P"!T?\`C7RIXKFB
MN_%VK2V[QS1/=,RO&=P(]0177@:LZT^6I%?<.Q)_PFOBO'_(S:S_`.!\O_Q5
M'_":>*_^AFUG_P`#Y?\`XJL*BO3]G#L@-W_A-/%?_0S:S_X'R_\`Q5'_``FG
MBO\`Z&;6?_`^7_XJL*BCV<.R`W?^$T\5_P#0S:S_`.!\O_Q5'_":>*_^AFUG
M_P`#Y?\`XJL*BCV<.R`W?^$T\5_]#-K/_@?+_P#%4?\`":>*_P#H9M9_\#Y?
M_BJPJ*/9P[(#=_X33Q7_`-#-K/\`X'R__%4?\)IXK_Z&;6O_``/E_P#BJPJ*
M/9P[(#=_X37Q5GGQ-K.._P#I\O\`\57<:?X9^+.K:;;:A::UJ+VUU$LT3?VN
MPRK#(_C]Z\JK[!\"`?\`"O\`P]Q_S#H/_0!7!CZOL$N1+7R%$^<?$&I>//"V
MIG3M6\0ZM%=>6'`35'88)SZ^E9)\:>*_^AFUG_P/E_\`BJZWXY<?$1L<?Z+%
M_6O-:ZL.HU*49M*XS=_X33Q7_P!#-K/_`('R_P#Q5'_":>*_^AFUG_P/E_\`
MBJPJ*U]G#L@-W_A-/%?_`$,VL_\`@?+_`/%4?\)IXK_Z&;6?_`^7_P"*K"HH
M]G#L@-W_`(33Q7_T,VL_^!\O_P`50?&OBO'_`",VM?\`@?+_`/%5A4'I0Z<.
MR`^TO#TLDWAK2I97:21[.%G=SDL2@))/<T4WPU_R*NC_`/7E#_Z`**^3G\3&
M?%]!Z44'I7UXC[!\"?\`)/\`P]_V#;?_`-%BO(/VA?\`D/:(>_V:4_\`CU>O
M^`_^1`\/?]@VW_\`0!6?XO\`ASH_C6ZM+G5)KR-[9"L8MI%'!]=RFOF:-6-'
M$.<MD,^3MH]!3E=XG$B,R.ARK*<$'V-?1_\`PH3PC_S]:M_X$)_\15BP^"/@
M^PO5N"M]=[.1!<3`I^(503^=>I/-*#6E_N%8[/PU<W-YX6TFZNRQN9K*&24G
M@LYC4GZ<UY#^T*Z9\/PX!FS,PYZ+\O\`];\C7L>J:K8:!IDEY?SI;6L(^9V[
M>@P*^5O'OBV7QEXEDU'8Z6L:&*UC/41]C]3D_E7!E]-SKJ:V0I'9^!/A#I?B
MWPI!K-SJ%W#/+(X*QHI'!QT-9/Q-^'%CX&M=/FLKNXG-T[QL)5`Q\OM7K7P6
M`_X5M9#`_P!?+_.N:_:%`&F:&<?\O#_^@UO3Q-5XODYM+VL,\%->D^$/@[J_
MB.WCO[^4:;8N`8RZYDE'J%[?C^M0_"+PA#XD\5&YOH=UCIX$KHXR)'/W`1Z<
MYQ[5]*7][:Z78S7MU(L5O"A=V/8"ML;C94Y>RI;]PL>:Q?`/PI''^]N]7E?N
MWG(/TV5EZO\``&Q>-VT;5KF*3^&.\"NK_BHR/RK+U3X^Z@]\W]D:3;BV1L*;
MG<TCCUPO`KN?A]\3K;QI(]C<V_V+4D'F>6&W)*OJI_I7)+Z[3C[63T%H?.WB
M#P[J?A?4FT_5+1H9NJ=U<?WD/<>QKO?@/#')XYN9&P3'9N5R.F2!_(FO8?B%
MX1M_%WA:XM&C'VN)6EMI".5<=OQKP/X6Z]%X=^(%J]X1%#<!K>7<,;">!GZ'
MK76L2\3A9I[H=CZGN7:*UFD099$9E'N!7Q;J=_=:KJUS?WDC27,DC,2_)7D\
M9/85]J'YAZ@CH.017FNL_!3PSJVHS7<<MY9R2L6DCA92ASZ`CBO/P.(IT)/G
MZC/FC`]!1A?05]#_`/#/V@_]!;4?R3_"D?\`9^T(J<:OJ`]\)_A7J_VG0[L#
MYYVC^Z/RI<#@=NPKUWQ#\"=1TZUDN=%OTU':,^3*HBDQ['.TUY'+%)!-)%*C
M+(C89&&"I[@UTT<13K?PV(]6^'OPHT[QEX535;K4+NWF,SQ%8T!'RGWKJ_\`
MAGS1?^@S?_\`?"UYWX/^*VH^#="_LNTTZTN(Q*\F^20CD\UT'_#0.M_]`33\
M^OFM7GU88YS?(]`.B/[/NB@'_B<ZAT_N+6)K'P!O(8'DT75TNG`R(;F(Q[O8
M,,C/Y4V+]H+5DD7S]!M&3IA9F4GZ96O7_"?B:S\8Z%#JEHCHK$JT;CF-AU'O
M7-.KC*'O5'H,^1+RSN=.OI;.\@>&XB8J\;+\P(_I[UU'PZ\(6WC/Q#)IMW<S
M6\2VYF#Q`$G!`[_6N^^/VBQ))I>MQ18EDW03'U`P5SZ]36'\!O\`D>[DXR?L
M3_\`H2UZ$L3*>$]K'1BL=C_PSYHG_0:U#_OE/\*/^&?-$Y_XG6H?]\I_A7I7
MB36#H'AV^U18?/:TB\P1EMN[G&,UX^/VB+C_`*%>+_P./_QNO,I5,953<&W8
M9+??L]H(F?3]?.\=$NK?Y?S5O\:\E\1^&M2\+:DUAJUL89CEE<'*2+ZH1_6O
MICP!X_M?'=I<216SVL]L5$L3.&'(X(([<'\JY_XXZ5'=^"DU%8P)[&X4JW3Y
M6X(_E^M;4,96A55.KJ*QQ/P_^$^F^+_"L>KW>H74$DDKH4C08&UB*]XT32TT
M;0K'3$D=X[2W2!7;@L%4#/Z5\T>%/BGKGA/1$TJPM+&2W1V??*C$Y)R>0U?2
M'AK4Y=8\,:7JD\:I+=VL=PX4_*&9<D#\ZQQ\:RDW4VZ!$Y;QA\*=-\9:X=5N
MM0NK>0PK'MC4$#'?FO*?B5\-;#P1IEC<V=]<W$ES.T3"7:,8&>.*[?XC?%+6
MO"7BI]+T^TLIH?LZ.&F1R<MD]B/2O+?&/Q'U7QI80VNJ6UE%';RF5#"C*3D8
M[L:Z<'#%)1E?W!F!HFB:CXCU*/3]*M6N+B3DJO&T>K,>%KUK3?V?YI(@^J:T
MD3MC=%:P%]O_``-F'/T%=Y\*_"<?AKPA;221XO[Y!<7+G[PR/E3/LN./7)J'
MX@?$ZV\%7$-A%9M>ZA-'YWE%MJQKR,L:FMC*U2K[.B!@#]GW10/FUK4&/KY:
MC^E17?P"T:"SGF76+XM'&S@,BXR!GFL(_M!ZPQ.-"LU`/>5S_P"RTR?X^ZK/
M;2PMHEHJNC*2)6R,C&?NTU3QU]63H>1##X;/!!/3'KC^5!Z&E"E!M(Q@;>N>
MA(/\Z0CBO:7PZC/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&
M?%]!Z44'I7UPC[!\!_\`(@>'O^P;;_\`H`K!\?\`Q*B\"7]E:R:=)>&ZC:0%
M9`NW:W-;W@/_`)$#P]_V#;?_`-`%>0_M`1/)K^C&.-W7[+*"54G'S=\"OF:%
M.%3$\L]AFG_PT-!_T+\G_@2O^%6;+]H#3+BZ6.]T:Y@A;K)'(),?45X'Y,O_
M`#SD_P"^#5F#2[^_NEMK:TN)IY6VJJ1L2WX$<?C7K3P&%4?^"*Y]F$6>J:>-
MRQW5I<("`RAE=6Z<'BOF;XJ^#+?PAXCC-DNW3[Y#+$A))B9?OKG_`($N/][V
MKZ,\,Z?-I/A?2M/N,":WM(HY,'(W*H#8_&O*?VA7C%GH,;<2F29A_NJ!_4K7
MF8&<HXA16S&=5\%N/AK9?]=I?YUS7[0W_(,T+_KX?_T&NE^"_P#R36R_Z[2_
MSKFOVAO^09H7_7P__H-72_W[YB+7P!M8XO"VI70_UDMT%8_[J\?^A&M/XX7<
MMM\/7AC.U;BYCB<C^[G)_/'ZUSW[/NJ1M9ZQI3,/,619T7N1T8_GBNV^*7A^
M?Q#X#O;:VCWW,)%Q&O\`>*G)7ZD9%35]W&7EW`^4\5T?@"[DLO'FARQMRUVB
M'`QP3S7.N"K%2""#A@1@JWH0:[OX2^'9]:\;V5RL9^RV,OGRR8^7(Y"_GBO;
MQ$HJE)R86/J;`%?&OBJ$6WC#5X4X5;V0?FQ:OL6>=+6WDGE8*D:EF).,`"OB
M_6+O^U=>OKQ?F%S<22Q@@Y(+?*..^*\G*HOGD^@I'=^&/C'XAT"VCM+M(]3M
M8AA1.VR11Z;QU_$5V$?[0ED5'FZ!<@GLLJFO"_*G_P">$G'^R>*/*GSS!)_W
MP:]">!PTW=K\1GO/_#0FF?\`0!O/^_J?XU=TGX[Z%?7B6]WI]Y9+(VT3$JZ`
MD]R#D5\\^3/_`,\)/^^#5_2M`U/6[^.RL;&>69VQCRV^4>I.!C'UK*>`PRC?
M]0N?9B.K`.K`A@"".^>E?,GQIT>/2_'[W$*K''?0K,5QQO'#'^5?2=C`;33[
M6W?YGBA2,GU(`']*^?\`X_3))XKL8$8;X;,[Q[$YKS<O;C7T&RIX`^$T_BNT
M74]0N&LM-=CY2H/WDH'4C/`'O7IUO\$?!L2`/!>3^\D^?Y`5VF@6<-GX>T^W
MB4*B6T:C`P/N@UY'\4_B5XAT+Q7)HVDS):Q0Q(YD\L,[EAGO5^VQ&)J\L)6`
M[`?!?P2IS_9TPQ_T\-_C73^'?#&E^%;!K+287B@9BY#N6Y/UKYK_`.%N>.#Q
M_;;?]^(_\*]H^$7B35/$_ANZO-5NS<3I<&-6*A1C`[`48K#XFG"]65UZ@97Q
M\'_%(6/'_+X/Y&N(^`W_`"/5S_UY/_Z$M=Q\?/\`D4;'_K\_H:X?X"_\CW<_
M]>3_`/H2UM1_W&0CVGXBC_BWFN<#_CV/\Q7R*.*^N_B+_P`D]US_`*]C_,5\
MB5KE/P2%(]F_9ZR=5UW/_/"#_P!">O0?C"!_PK#5>!P8S]/G6O/OV>?^0KKO
M_7"#_P!">O0?C#_R3#5?K'_Z,6N?$_[ZOD,^5R/;M7V%X#_Y)_X=/?\`LZ#G
M_@"U\??X=Z^P/`7/P\\.GC_D&P?^@"M\W^"`HGA'QS`_X6&P_P"G6+^M><Q1
M"66.(\!V"?@37IWQXLY(/',%RZL(I[-2CXX)5BI7Z]_QKR[+)\Z\,OS#Z]JZ
M\(T\.DNPS[>C0)$J*,*!@5R7B'X:^'/$^JMJ.IV]Q)<2($)68J`!TXKH])OX
MM3T>SU"W<&&XA216]05S_6O)?BGX[\5^$/$R0V$D4>G36ZR0EXMP+9P1GU&"
M<>A%>#0A4E5Y:;LQG2#X)>#`,"UNL?\`7P?\*KWWP6\'0Z?<RQVMR'2)V4F<
M]0"1VKRK_A=OC3_G\L__``''^-,F^-/C&:"2*2[M"CJ58"``D$<]Z]%8;&7U
MG^(C@,\9!(#'</8<C]<4'H:4`C*_W3M(Z9.<_I2=C7LI>Z(^T?#7_(JZ/_UY
M0_\`H`HH\-?\BKH__7E#_P"@"BOD:GQLH^+Z#THH/2OKA'V#X#_Y$#P]_P!@
MVW_]`%;LEO#,P,L$;D<`L@.*^:=*U_7HM&LH[?7-0BB6%!'&CC:H].F<5;_X
M23Q%_P!##J/_`']7_P")KY^>!GSMW%SH^BOL=M_S[P_]\#_"G1P10Y,421[N
M3L4#-?.?_"2>(_\`H8=2_P"_J_\`Q--;Q%X@8;3X@U0CU\X#_P!EI?4:C^T'
M.CZ#O]2LM)M'NKZYBMX4&YI)6``_QKY=^)?C,>,_$OGV^X:=:H8[;/5Q_$Y'
M;=CI_LBH]7TZ^U0M)-J=U<R#H+F0L/P!Z5R<L3V\[QNI61>H-=^#P4:4N=N[
M"]SZ=^"P_P"+:V7_`%WE_G7-?M#?\@O0_P#KX?\`]!KS_P`-:UK-EHD<-IK%
M];6X9L1Q.`H_,52\8ZGJ>HPVBW^HW5WL8[?/<':?P`K.GA9+$^TOI>X^;6QF
M^%?$EWX3\0V^KV7.S(DC)QYL9^\I]_3Z5]4>&_%6D^*[!+K3;A7XR\3'YXSZ
M$?UKX\(W_*HSS72:+IM[93+>17EQ9SCH(6*OCT)'6M\9A(5?>O9DWL?2VJ?#
M_P`*ZS=M=WVB6TLY^\Z[E)/J<8%;&FZ3INAV?V;3[2&TMU&2L:X'U)[GZUXA
M;>.O$UM"L2ZM+*>FZ0*Q'Z5C:[K.M^((C'>ZU>[#_P`LU8(OXA:\Y8*K+W92
MT'SHZKXL?$FW-C-X=T6<2R2?+=7,;951_<!]3W/:O*?!*AO&^A(0"OVU/E(R
M.OI67?:?/82!95Q&?NLHXI=+EE@U:VEBD>*5)05=?X3_`(UZU+#QI4>2`7/M
M/[+;_P#/"+_O@4?9;?\`YX1?]\"OG4^)/$>?^1AU+_OZO_Q-)_PDGB/_`*&'
M4O\`OZO_`,37D?4JG\P<R/HO[+;_`//"+_O@4](TC7$:*H]%&*^<3XD\19_Y
M&'4?^_J__$U%/KOB"=&1O$&IX/<2X_D*/J$WU#F1[UX@\3:3X9L9+O4[N.)5
M&0A.78^@'6OE#Q7KTWBKQ%=ZM.K(+@D(I/W8QP!5K5-'N[EVNC>3W<GK/(6;
M'L37.LN/E*G*MSNKT<'@X4M6[L5^8^J?AMXPM/%'A>R02J+^WB$4\.[GY>,C
MVK;UGPCH'B"19-6TFWNI5P`[@AL>Y&*^5=#TZ[#K?1W4]J<X5H7*L?Q%=K'K
M_B!%"C7]3&.,^:#S^5<E7`6J-TY#YTCV/_A5W@D'/_".6O'N_P#C6WHOA_2_
M#UHUMI-BEI`SERD9)!/KS7@G_"2>(_\`H8M2_P"_J_\`Q-)_PD?B(#_D8=1`
M'_35?_B:RE@JLEK,.=';_'S_`)%"Q_Z_/Z&N(^`O_(]W'_7F_P#Z$M<_XNU;
M5;_3HX[[5+V[B$N0L[`J#CM@"LOPE>WUAK$CV5W-:2F(C?`P#8ST.17=3PS6
M%=.^XKZW/IWXB#_BWFN<?\NS?S%?(F.*]%UGQ!KUQHUW%<:Q?RPE,-'(Z_,/
M?`Z5YT1Q5X##NDFF]QWN>R_L\_\`(6UW_KA!_P"A/7H7QA_Y)CJOUC_]#6OG
MWP?J-_87=X=.OYK-I%`)A8`G!/7(K:\2:UK5UH=Q!=ZM>W%NY7,<SC:2/H*Q
MK824L3[2XN=(X`\`\9]O6OI+X.^+K;5/"UOHDTR+?V'[E49L>;&/ND?AQ^%?
M-N#VP#6KHNGW%Q,+N*:2V"$;9(V*L"/0CI77B\/&M3LV.]CZ[UC0-*U^W$&J
MZ?#=1J?E$@Z9]".?2O%/C)X.\/\`AK1--GT?3([.66X8,R;CD;1V)-9,.O:_
M!&J+X@U,(HQGS0?S)%8'B_5M2OK.U%_JEW=QI,2HE;(!QVP!7GX?"U(5$U+8
M.9'<?"3XDVVG6\?AO7)Q%&IQ9W).4'_3,GT'8_AZ5[5<V.FZY9@75M:WMN<E
M=ZB0<\9![?A7QK9:?+?2M'"H8+U)'`'N*[+25U31T"VVM:A",<I%*0H^@.:U
MQ.`BY\\)68<Z1]!'X>>$B<GP_9$GT0C^M5K_`.'WA2/3KITT"S5EA<@A3D$*
M?>O'QXD\18VCQ!J0`[F5?_B:9/XC\0M!*K:_J#*4(*F08(QT/RUS+"5D_C#F
M1YAG*].><=^,"D/0T`G;NY.0<C`'?K0>_%>\E[H7/M#PU_R*NC_]>4/_`*`*
M*/#7_(JZ/_UY0_\`H`HKY&I\;*/B^@T4&OKA';Z=_P`@RS./^6256U35GTZ6
M-!`CJR[LDU9T[_D&6G_7)*Q?$B,]U`R*Q&S^%<URQ492U,8_$+_PDLO_`#Z)
M_P!]4Z/Q/EE$MJ-O^R:PO*D_YY2?]^S3H[:>4JB0R_-_L5MR0*Y4=S&RR1AQ
M\RNNX$=JY_Q+"JSP3J!N?Y3[UNVD3P64$3D%XTV\5@^)95+V\2L-R_,U94_B
MT)C\1HZ%_P`@F,CU:J?BGF*#//S5<T+_`)!,?U:J?BC_`%,'^]50_B%?:*F@
MV23WCS.N4B7TXW5T]S<1VD$DTAPJ#-8_AM,6$K=RW-2>(79=,(`X=U6B>L[`
M]78RI]?O)9&9&1$[#&<5I:3K4EY-]GN0-_4$=#7,8Z\59L79-1MW7J)`#6DJ
M<4KE2BN4Z^_M4O;.6%NNWY3_`':XR"0V]R'9.4;)'TXKO<#GBN$OD"7\^T_\
MM#4T&3$USXE?_GV'YT'Q*W_/L/SK!"L3@#=3Q!,5SY,A7U$9JO9Q'9&V?$K\
M_P"C#\ZF@\2H\BK-;,H[$'I7/FWG'_+"3_OD_P"%2V]A=SR*B0R`'N4QBIY(
MBY4=OC+;L[E(SD5R>OVZP:@VW`$@SS75HGEQ1KD':FVN:\3-_IT8'WE3FLZ7
MQ!'>QT=N@2VC1>-J*?TK#U;5KFSO6AAV(JC.-N<U>TB\2\LT3<OF(-I!/)JW
M<V-M=E3-"CL!C=TQ19*7O(E>[+4Y8:]J(_C3_OFMW1+N6]LVEG?>X8CIBI/[
M$T__`)]Q^9JS;6D5G$T4*!%)S3G*+5D.31E^)O\`CQC_`.NE4?#H_P")@P[>
M5_6K_B;_`(\(_P#KI5#P[_R$3_UR_K37P#C\)N:F!_9ESQ_RSKBFX4_2NVU/
M_D%W/_7.N(;[IX[4Z!43?\.#_2+L>P_F:TM=`_LJ;IU%9OAS_CYO/H/YFM/7
M?^05-]12G\9+^(X_N"<8[UVFDQB+2[0+_P`\P?KG-<41QVZ5VVG#_B6VO_7%
M?Y&JK[#D4=;U6:QE6&WP)"-Q;'05@W6I75W&%E8-Y?(XQ5OQ!_R%3_NUEH`S
M@'H2,U5.*Y;@E[IV6EVB6>GHJJ2S#>Q[U5UC5GL)5MX8U:7&XL>PK8"A<*O`
M`'\JKSV%G/-YDEO&[8P20:P37-J1U.<.OZ@>\?\`WQ2'7K]@03'@CGY.U=#_
M`&1I_P#SYP_E3)=)L!#(5M(@0I(('3BK4X]BKHXWD*-PRPSG\:0C@T'/S8&%
M#$4'H:WZ&A]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH/
M2B@U]<([?3_^09:_]<DJT1GMG\*JZ=_R#;;_`*Y)63XAGF@GA".Z;E_A:N5*
M\C*UY'0;?]G]*7&.@QCO7"?;;K_GYD_.GP:E?0,K)</N]":T]DQ\IV=V9UMF
M:WC1IA]T$UQ$\DLMS(T^?,W?-N'2NV@<S6R3E"ID7=CTKGO$ENL=U%,J\2KA
MO^`U-)V=@CO8T]"_Y!,?U:J?BC_4P?[U7-!!.DQ\=VJGXH'[J#C^*G'^('VA
M/#4ZJ9H&'SL-ZBM75+,WMC+$@P^,K7&VTSVUPDT;8=6R0?2NOL=3M[Y%VL$E
M[HQY_P"`^M$XM.Z"4=;G&R1O&[(X967^\*U-"T^2XO5G*8BC.=S?Q5U+P12'
M+Q(Y]2M.<QPKEF6-%_O'%#JMJP<XCN(XG<G`5>I[UQ$<<E_?F-/O2R$Y'\-:
M6L:PLZFWMV_=Y^8_WJC\.HK:D7/\*$TXIQ5V-*RN;]IIMK91J$B4M_$[=35W
M&!P,#VI'.U6;&2`37$7.H7=S.9&E<`G@!L;:B*<NI*5SN,'WHP1R,@^M<%]I
MN/\`GO)_WU09YF_Y:R?]]57L/,?*=K<7EO:0M)+(@/\`<_B/X5QE]=M>WKS,
M"N_A#Z"H22W4DGU-'?\`&M(041K0%8HV5.T]>#BK(U2]5<"ZE7\0:W]`A633
M,O"K'>><9K4^SP_\\(_P2IE42=K!*1QW]KW[?=NI#[8%=/I'VIK)9+HN[L>`
M_&*NK;Q)]R%!^%1SW$-NF9I$1?\`:;FLY24E9(3=S(\2G%K`.[L:I^'?^0DW
M_7+^M5=3U'[?=AE&(8^%5N"?>K7AP'^T'XY\JM+6AJ%M+&[J?_(+N/\`<KBM
MK>A'_`:]!*Y&"N?PI/*7^X/RK.-3EZ`G8P/#=NZB>:0%4;H",$U=UYE72)">
MI8"K\CQP+F1@BCNQZ5S6N:E'<M%!"<Q(<D^I]:(WE*X;R,4]Z[C31_Q+;3_K
MDO\`(U0T&VBDTI6>*-\L>66M=454"*I11T`%.L[JP2EI8Y7Q%QJQ_P!VLK&3
MBN^:V@D;+P(Y]2M8GB*"*&TB9(U7+=`O6KISO[H1E?0U[>=9[6.=.3(H;'Z5
MC:Y-?VUT9(II5A*@97H#Z57T?5A:*;:X&82<JP_A]JZ2.2"Y0&-TD4CH#FH:
M<'<-G<XW^U;[_G[?_OK_`.M0=5O3]ZZ<@]1G_P"M79_9X_\`GFO_`'S4<\$8
MMY2(E^XW\/M351=@N<(2Q!W'.3FE/0TI'S-Q_$:0]#6[-#[0\-?\BKH__7E#
M_P"@"BCPU_R*NC_]>4/_`*`**^1J?&QGQ?0:*#TKZX1V^G?\@NS_`.N253U?
M2IM0EB>)U&U?XJ2RUBPAL8(Y+A494VMPU6?[9T[_`)^E_P"^&KF?-%W2,?>Y
MC%_X1J[_`+\7Y4Z/PU.73S)T"_[(K8_MG3O^?I?^^&IC:WIH_P"7G=_P!J?/
M/L/FD:"1JD:Q*N%5>]<YXGF1IH84^\B[FJW<>([=$98$:5O]JN9FFEFG:61M
MTK-NW55*#O>0XQUN:EEH]S>VRS1W*QH[;>AJ'4M.N+)(C+,LFYMORC-:FD:C
M96VG)'-*%DW;L;:K:_>6MW'`+>0,R-NX6G>7-L/4Q,=Z.AR.".GM1VHK4LG6
M]NE7:MQ*JCT;-,>>:9MTK.S>C-4>*"*!6#M6GH,ZQ:HF[Y0XVBLRE!(((Z@Y
M%*2NK$GH)`(Y%<[=>&F>4O;3!06+;66EL_$:;5CO(W/8.HK0&MZ<RY-SC_>2
MN:TX["Y7$Q_^$:N_[\7Y4?\`"-7?_/2+\JVCK.G?\_2_]\-1_;.G?\_2_P#?
M#5?//L+FD8O_``C-X>/.B_*LJ2-H)7C8@LC%3MKK_P"V=.S_`,?2_P#?+5R5
MVR/=S,C!HRY8$>]:0<GN7&_VB(2R(,`D?0TOG3?\]6_.FXHQ5E"^;+_ST;\Z
M"2?O$GZTE%`!CO2@E3E20?8XI**`'>=+_P`]6_.CSI?^>K?G3:,4"L*69ARQ
M/U-)CVHHIC'"61<J"P'3@UV^G\Z;:DG),*_R-<,1D8]:ZNSUBP2R@BEN%5E1
M0?D;T-95DWL1(RM?E=-4(#$#;V-91DD;AF)^IK1UNY@N]1\V!@R%<`A?2LRJ
MI_"./PB]O:E!*\J2/H<4E%44.\Z7_GJWYT&64@@R$CZTW%&*!6#M0>AHH/0T
M,9]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH-%!Z5]<(]
ME\-_!&RUWPWI^K2:U<PO>0+*8UB7Y=U:G_#/5C_T,%Y_WY6NX\((TOPFTM(U
M+.^E*JJO?Y*^;D\#^,-H!\.ZSG'/^CO7BTJU6I.:=7EL,[_7_@1J&G6,]YI6
MIK?N@W?9Y(=KGW5MWWJI^!?A):>+O"D>M/J\]LTK,OEQQ+_#7KWPVL-4TWP#
MI]KK"R+>)YA,<C?-&NYMJG\*I_"9H9?!#O!M^S-?W1BV_P!WS3M_2L98VLE)
M<U[.U["L?+*G<BMZC-+7M.G:+\&XKR#1FGN+V\+B$32/.%:3[O\`#M7K6/\`
M%?X<Z=X.MK34]):1;6>7R'@E?<4<*S*RM][^%J]2&-@Y*$DTWM<#R[WHP*]J
MT#P%X$T[PA%K/B>^2YG>W%Q)&MWM\M6&Y555;=NQ5CP[H7PE\:74NG:587L5
MVB%PKSS`X'=<NRFIEF%--V3:6[Z`>&]J*]&N/`%IHOQ<T[PU=/)=:?=%7`9B
MC/&VX$,R^ZUW7B7P-\,/"K6UUJZ7-O;R;D6W2>9S(WKP=WR_UIRQ]--))N^U
M@/G^BO;/''PT\-6_@[_A(O#J26ZJJ2A3+(ZS1MZAN5ZUMZI\+?`5CX<BU.]$
M^GQ(D4D]P+B1^#C(VMN^]TZ9YJ?[1I63L]78#YXQ17OF@>$OA1XO:XL]%AN&
MN84W,3+<*R@\;AO.WTK,O/!WPR\%71L_%&HW=Y>/ET3,H\M.W^KI_P!H0OR\
MKOVL!XM17N/B[X7^%CX)G\0^&5FMQ%!]H3]X[I,@Y(*O\U8_P]\`^%=4\.G6
M_$M^A+%BMM]K\H*J]SC#9H6/I.#G9^G4#R:C%>U:79_!C7]7BTFQL[L74[;(
MBTUP`S>QWUSOQ"^&J>&=>TVWTF21[74I!'$LIW/%)GH#W'>JAC82ERR35^X'
MF]'%>^7GPV^'W@G1X;GQ3+<7$DC>7YADE`=\9(58N?SI^D_#_P"&GC;3KEO#
MRW<,D)V/(DLV8W(R#B0D'\*AYA3M?E=N_09X!17HWA'X9-K7C'5='U*X=+32
MI-DYC7!D)/RA3[]3[5U&IZ?\%M!U*?2]06<W=NVV4"6Y;:1_NG;WJIXZFFHQ
M3?H(\1HKV7QM\+]`@\(OXG\+32BWCC6;8\A=)(R>JD_,#S5O0/AOX8O_`(6)
MKT]C(=1:Q><2K<R`!PIQ\H;':CZ_2Y5+SL,\0H^AP>QK>\$:7:ZWXTTC3K]#
M);7,VR1`^"1M8]N>HKT7Q[X*\%^$O$'A[=:RVVE7,CB^/GR.2H''5L]?3FM*
MN+A"?L[.XCS-_"NOQZ<=3DT:]2R$8D\_;\H0]_Q-8QP%)(X`Z5]=W_\`PCG_
M``KUA<F3_A'3:KD@R;O*XQ_M>GO7B/BQ/A2/#5W_`,(U)-_:J@>2&-QUSS]_
MY>E<^'Q[G=.+^7Z]AV':I\,-*T[P&^OQZ_YERELD_P!G^3EB0,9'/1J\Q[5[
MAKOPZ\,V/PHEUV#3Y5U!;&.<2&YD;#,5W?*6V\@TSPW\+/#-EX07Q%XNFE=6
MB$\B(YC2)3]W[G))!%32QD8Q;DV];;`>)48KWG0O#OP@\5WKZ=I%O<&[VEL>
M=<*<#ODG!K@/%/@`:!\0;3PZEZ/LMZ8Y(IYR%V1EBIWD\$C!Q713QM.4G%II
M^8K'"XP*,9X]>*]UU;PM\)_!UC;?VLTU_+(WEATNG:1B!GD1LH`Z5/IGPZ^'
M?CG0I[KPTMY9LCF(2&21MDFT'!#E@1@KTK/^T*>[B[=[`<!\-O`-OX\?4Q/?
M3V@M?*?:B9SO+<Y_X!7->*]#C\.>)[[2(YGF2UD\L2.N,\9KUSX"VLEEJ?BN
MTF`$L#P1R?+M^8-+S^(K//@FV\:_&OQ%;7\LB6=L1+(L9PSY(`&?0UE'%N->
M;<O=2"QXWVI:]N\1Z?\`"#POJ\FE:EIM])>1@-($EG.`WS`_?`[]A6;XN\&_
M#^3PI-J_AC5[>"Z2$7"6SWPD,B]UV,VX-V^M;0Q\9-7BTGUMH!Y%0>AHH/0U
MW,#[0\-?\BKH_P#UY0_^@"BCPU_R*NC_`/7E#_Z`**^1J?&QGQ?0>E%%?7"/
MK3P5*UM\+=&N``S1Z;'(N?\`<KR-?V@_$14'^R=)Y'I)_P#%5S5G\4O%>FZ/
M%HD5W;I;0P^0D9M58^7C^]]*XP+@#':O+H9?'GFZJO?8+GH6N_&3Q5K5C)8[
MK*QAF#K(UK&VXK_O,S?^.UZU\%ACX96W_7>;^=?,==?H?Q(\4>%]'73M-N+>
M.T1V**]NK'/\57B<%S4N2DDM;@<_X9_Y&#2/^OJ+_P!"6O?/V@!GP;I@/0ZF
M@/\`W[DKYYM)YK&[MY[=]LL,BLF?[W\-=)XE\?>(?%6G16>M7,4MO#,)E`@5
M#NVL/X?]DM55\-.=2$H[+<+GT!/:P>!/`JW?AGP\FH7,<,8$5O'^\G!VY=BJ
MEF_O5F^"?%.L^(_$)_M;P0VF&.)F2^>W>/:<\IN9>]>.:-\4_%N@:=%:VNHI
M+:PC:B74"OL']T,/F_.K;?&;QO+=QN-1MT(Z1+:KM;_>KC>`JZJR=^MPN=[X
MN_Y.'\-?]>\7_H<E4/VAA^]\/\=IOYI7G%[XX\0:AXEM_$5U-&VH62+&DJPJ
M$7EBN5_BY-0^*?&6M>*S:G7)HI#;[O)(@5-H;&?N_A6U'!U(5(2=K+<+E,Z]
MK$ULEA-J]^]D<1^0;AC'M!^[MW;:^A/BJ/\`BS4W_7.V_FM?-`X8,.HYKK-7
M^(WB7Q!H;Z+>W-O+:,$#*MLJ-A<;>?RKHQ&%E.I"4+63NPN=;^S]_P`C9J?_
M`%X_^U!61\;./B3<_P#7K%_6N8\,^*=5\*W<]YHLRI--%Y;LT*OP&']ZJ_B#
M7M1\1:O)J&J2JUVZJC,L2ID?\!H5"?UEU>EK!<^B(./@*3V_LD_R-0?#O1=.
MT7X:6FL:=I:7NI2VS3L57][,V3A`W;IC%>,#XE>)(?#O]@?:K=;'[.8#']F4
MML.<_-4?AKX@>)?"]J+/2M0;[.YWK#+$L@S[%N5KC>!JN,DGUOZA<]?T+QKX
MB\0^)+"TU7X?2P6QE'^DR6T@^S$9^?<Z;>/;UJ3XL74=KXB\&SRL%CCO\L3V
M[5YE/\9O&TQ1AJ$$*J<G9:IS^=8/BCQOKWBO[-'K5S'(+9BT16$(<X_V:J&!
MJ^T4FDEZA<]L^-V@:MKNA::VE6$]XT%P[21P1[W`*8R!7#>!?A+J^L07<VIS
M:CH>UAY2M#M9^.NUNE86E?%GQCHT"6L>I+/%&FV-+J!7P/3<,-^;&I;_`.,/
MC6[MGA;4(+9&!#-!;+N/XFJAA\53@Z4&K=PN>C?".V@TSQ+XLT9+MKF2WG7$
M[_>D4<;C^.:L^)/%WC72M>N[.R\#+?6BR'R+E()'$B>Y48!KP+2M8U/1]234
M-/O)H+P,1YJD$DGDY!X-=JOQM\:P1[9+JS<CC?):KN/X+Q2JX&I[1S5I:==/
MR"YZ?XHN?%T_PZU&XU.UT6RMGLLRP_O/,CSC(Y^7TJ[X(A>\^"MM!;+OEDT^
M1$4=2VT@#\Z\(\0_$'Q/XJMA9ZGJ`:W(W>1#$J(<=V[FF>&O'7B7PS;-!I%Z
M5LV.3!+&LD8/J`>1FI^H5?965D[W"YTOPU\#^);;QYI=W=Z+>6MM9R;YI;B+
MRUQM88'][D]:Z;]H;[NA]^)?Z5Q-W\7_`!M=O&YU*.`1'>$@MT`;ZYZBL;Q1
MXRUOQ;):IK<\4GV<MY6(53KU^[6T</7E652I;0+GO][;3ZK\$%@LH9+B>;2X
M_+CC&6?[IX'K7F$/PA*>`)_$&K7UU87<4$DK6<EO@+C[H.[G)XKGM$^)OBKP
MOIZ6%E>HUM&,I'<Q"3:,_P`)Z@>U,\0_$7Q5XFLFM-1OD%FY!:&VA6-9/<G[
MQQZ=*SIX7$TY-0:LW<+GMOBG/_"A)L#G^S(?YI4OB.TG\0_!)X-(C:YFGL(6
MACC/,@#*W'J<`UX9=?$GQ)?>'6T&XN;9K!H%A91;*&"+@CFF>&_B!XI\,6RV
M6E7["V`+BVEC21%'J"W(^E9K+ZUN96NG<+FKX/\`AEX@UC7S;W]IJFC0!&)N
MVMFC.<],]ZV#X$T_3_C!HGA^^U*758)8S/,MP,=%=EC(W'(X!Q_M5ES_`!K\
M;31E1=6D`QRR6PS7&3ZOJ=SK0U2:\N'U/S1()R^6#CG*GL/:NE4<5.3YVDO(
M+GTGXT\0ZGX.CM+3P_X/-_;R+AV@A8QQ@=`51:T?`.HWFK:3<7U_X:.A74ER
M0\1B,?G?*N),%0?;G^[7AMM\:/&T,:Q?;+:9@,!I+9=WU)[TQ?C)XXB>4G48
MW!8DAK2/"C':N1Y=6Y>6ROWN%ST3X/?\CCX\X_Y?$_\`1DU9NFPZVWQQ\3S:
M%<:>LT2@S0WH<)+'A.05[AL5YOH'C_7_``Y>:IJ&GR6XEU&42W+RP*06RQ&`
M.G+-5-O%VM'Q9-XCM[PP:I*V]I+=0JD'C!4\'Z&ME@JKE)Z:JP7/=]>\=^)=
M$U5]/G\!3:HJ!66YM#(T;D]0/W+=/K_#5C6M$TKQ9\.+K4]4\.1Z5>_8I9D6
M2,+-:LJL1E@%..,X/7TKR@?&[QK&@5[FQ..-TEL,GW^6LC7OB/XL\36$EK?Z
MB19O_K(8(UB5O0$CYB/8U$<!6YDTDK=;L+G(GC=MRWS%05Z$#O0>AHQQ0>E>
GRP/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&?__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
